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METHODS: Treatment failure (TF) in children suffering 
from RTI was derived from the German IMS Disease 
Analyzer–mediplus database totalling 20% of all treatments 
with clarithromycin suspension. TF is due to non-sensitivity 
to clarithromycin or incomplete intake of medication (non-
compliance). The TF rate due to non-compliance on the clar-
ithromycin suspension (13.5%) was calculated from the overall
TF rate (20%) minus the average TF rate due to non-sensitivity
(6.5%). The TF rate due to non-compliance on clarithromycin
SipTechnology was 1.75% as estimated from clinical trial.
Resource utilisation data for treatment of RTI and TF were
obtained from a Delphi panel of paediatricians. The analysis was
conducted from the perspective of the German Statutory Health
Insurance (SHI), including direct costs for physician visits, 
laboratory values, drugs and hospitalizations. Cost data were
derived from published sources for the year 2006. One-way sen-
sitivity analyses were performed. RESULTS: The average costs
of TF totalled €118.05 per case. With an RTI incidence of 
about 426,000 cases among German children aged 2–12 years
and a reduction of TF from 20% to 8.25% (remaining TF 
due to non-sensitivity plus non-compliance on clarithromycin 
SipTechnology) for clarithromycin SipTechnology compared to
clarithromycin suspension, the annual cost-savings for the SHI
amount to about €5.9 million. Sensitivity analyses conﬁrm the
robustness of the results. CONCLUSIONS: Due to its improved
compliance and consequently decreased TF rates, the treatment
with clarithromycin SipTechnology is cost-saving for the German
health care system compared to clarithromycin suspension.
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OBJECTIVES: To examine use and cost of inpatient care by
severity of COPD during one year. METHODS: Using
2004–2005 Massachusetts hospital discharge data, a cohort of
patients with COPD (ICD-9 principal diagnosis codes: 491.2X,
492.X, 493.2, 496) assigned to v15APR-DRG 140 (COPD) was
identiﬁed. A COPD inpatient stay proﬁle was established start-
ing with the ﬁrst hospitalization (index stay) at any Massachu-
setts hospital in 2004 and included all subsequent inpatient stays
for COPD within twelve months. Cases were examined by APR-
DRG severity (mild, moderate, major, extreme). Charges (accom-
modations, ancillary services) adjusted by a 0.652 cost-to-charge
ratio, medical inﬂation and geographic factors are reported as
2006 US$ costs. RESULTS: Of the 11,279 patients 60% were
female, mean age was 69 years. More than half (54%) were clas-
siﬁed as moderate severity; 22% as major, 21% as minor and
4% as extreme. For all COPD cases, the mean LOS was 4.7 days
with a mean cost of $6671 per hospital stay. On average, LOS
and cost increased by severity level from 3.5 days at $4745 for
minor cases to 9 days at $15,997 for extreme cases. The inpa-
tient case fatality rate (CFR) during the index stay ranged from
<1% (minor severity) to 18% (extreme severity). During the sub-
sequent year, 5044 (46% of index survivors) had a COPD-
related readmission. The readmission rate was 39% for minor
cases (mean: 2.2; range: 1–15), 39% for moderate cases (mean:
2.1; range: 1–18), 38% for major cases (mean: 2.1; range: 1–12)
and 20% for extreme cases (mean 2.3; range: 1–10). CON-
CLUSION: Almost half of patients receiving inpatient manage-
ment for COPD will require multiple hospital admissions within
a one year period. Severity of illness impacts duration and cost
of hospital stay, inpatient CFR and readmission rate.
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OBJECTIVES: Recent federal legislations has mandated phar-
macies to move pseudoephedrine (PSE) products from over-the-
counter to behind-the-counter. We undertook a qualitative study
that explored the public’s perceptions about this new policy.
METHODS: Ninety participants comprising of physicians,
patients, and pharmacists responded to questions about per-
ceived advantages and disadvantages of this policy, its inﬂuence
on the treatment for a common cold, barriers to implementation,
and personal impacts. Qualitative content analysis was per-
formed through the immersion and crystallization process to
identify emerging themes and salient topics. RESULTS: Advan-
tages included more opportunities for pharmacist counseling,
decreased access to pseudoephedrine by minors, less likelihood
for misuse to occur, and less shoplifting. Disadvantages included
rising prices for other cold remedies, less consumer autonomy,
and more pharmacy workload. Implementation barriers involved
lack of consolidated purchase data between various pharmacies
as well as discrepancies between store versus pharmacy hours of
operation. Impact on treatment of colds consisted of substitution
with other over-the-counter remedies and frequent clinic visits
for prescription drugs. CONCLUSION: This exploratory study
suggested actions that might improve the desired effect of the
pseudoephedrine legislation: 1) establishing a universal system 
of linking purchase data among various pharmacies; 2) reducing
the discrepancy between pharmacies’ and stores’ hours of oper-
ation; 3) providing additional support to help the pharmacy 
staff adapt to their new regulatory roles; 4) enhancing 
public awareness about the policy; and 5) studying the economic
effects of this policy on the costs of cold remedies and health
care expenditures.
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OBJECTIVES: The burden of chronic obstructive pulmonary
disease (COPD) and asthma could be reduced through appro-
priate medication therapy management. This study examines 
the relative propensity of Maryland Medicaid managed care
organization (MMMCO) patients with COPD and asthma or
either alone, to be prescribed ﬂuticasone/salmeterol combination
(FSC). METHODS: All medical and prescription claims for
MMMCO enrollees with a diagnosis of COPD (ICD-9 codes
491, 492, 496) and/or asthma (ICD-9 codes 493) in the primary,
or secondary diagnosis ﬁeld, were retrieved. Study patients were
40 and older, claiming at least one FSC or other COPD drug
with a minimum 30 days supply. The propensity of being pre-
scribed FSC was estimated as a logistic function of patient age,
gender, race, general health (as measured by the Charlson
Comorbidity Index), and diagnosis of COPD and/or asthma.
RESULTS: Out of total 9131 patients, half were African-
American, 70% were female and over half were over 50 years
